Lab

Life Sciences & Healthcare

United Kingdom

Discovery, innovation, market awareness and understanding are key to those life sciences and healthcare entities providing services and finance towards, and developing therapies and services for, the improvement of patient outcomes.

Due to the highly regulated nature of the industry, as an operator, investor, adviser, developer or licensee, you will be dealing with complex legal and regulatory requirements to launch, maintain and deliver your products and services to the market.

Our Life Sciences team is immersed in the sector and we appreciate our clients' technology; we are not just lawyers, we are immunologists, geneticists, chemists and engineers. With this background we are ideally placed to really understand your business, how it is changing and what you want from a trusted advisor. Highly relevant to this sector is our fully integrated European patent attorney practice. Spanning multiple disciplines, both legal and scientific, our lawyers and patent attorneys operate as one team with a common outlook and objective for our clients - providing pragmatic, innovative and effective advice, efficiently.

Our Healthcare team is truly immersed in the sector with over 25 years of advising and shaping the sector through in depth experience, knowledge and sector associations and collaborations. We have significant experience of working within the public and private sectors, giving us a complete perspective of the issues you face, allowing us to offer you commercial and well rounded advice.

With active memberships in major industry bodies such as the ABPI, ABHI, BIVDA, EUCOMED / MedTech Europe, Healthcare UK and the BPF, we help shape the legal and compliance frameworks impacting the life sciences and healthcare sectors.

As well as clients' significant, complex and strategic transactional, financing and structuring matters, we regularly advise on day-to-day business operations, covering areas such as public procurement, tax, competition, IP protection, exploitation and enforcement, product liability, supply chain, outsourcing and other commercial agreements and employment and pensions matters, as well as regulatory, disputes, risk and compliance advice. Truly a full service.

Read more Read less

"A one-stop-shop for us: its remarkable and successful mix of talent makes it stand out from the rest, and makes our lives much easier."

Chambers UK, 2015

Choose area

    Biotech

    Recent years have seen an increase in the numbers of biotech IPOs and more investment in the sector, however it can still be challenging accessing the finance necessary to fund R&D and to bring products to the market. As part of the biotech industry you will expect your lawyers to assist you in tackling these difficult financing and market challenges. Our team of sector specialists, including lawyers with technical backgrounds, understands the commercial drivers in this industry and can advise you on the full spectrum of legal matters.

    Read more

    Devices & Diagnostics

    In an increasingly competitive healthcare market, medical device and diagnostics companies need to ensure return on investment when developing innovative and reliable medical technologies and services. Devices and diagnostics are subject to complex regulatory and compliance frameworks and are often subject to competitive tendering so you will need lawyers who can reliably advise on pragmatic, compliant solutions.

    Read more

    eHealth

    With technology and digital innovation at the forefront of many advancements in the lifesciences industry and in healthcare delivery, organisations look  to consistently push boundaries to bring products and services to both the consumer and professional market. However, the regulation of ehealth solutions, devices and services is often outpaced by the novelty and innovation in the solutions themselves and at CMS, we understand the challenges this presents.

    Read more

    Healthcare

    The healthcare sector in the UK and internationally continues to experience a period of dynamic change underpinned by significant legal reforms and devolution to the four British nations. As an owner, operator or service provider in this sector, you are facing a highly regulated environment combined with increased public scrutiny. With increasing opportunities for the private provision of healthcare along with an ageing population, but with shrinking public healthcare budgets, operating within the healthcare sector presents both challenges and opportunities.

    Read more

    Pharmaceuticals

    With ever increasing costs of gaining marketing authorisations for new drugs, fewer opportunities for blockbuster products and ongoing pressure on pricing, operating successfully in the pharmaceutical sector can be challenging. Our sector-focused team, many of whom have technical backgrounds, are able to help clients overcome these challenges and maximise the commercial opportunities.

    Read more
    High­lights of our ex­per­i­ence in Life Sci­ences & Health­care...
    Law-Now: Lifes­ci­ences
    Vis­it Law-Now for leg­al know-how and com­ment­ary

    Feed

    Show only
    24/08/2018
    Gov­ern­ment Is­sues Brexit Tech­nic­al No­tice for Life Sci­ences
    On 23 Au­gust 2018, the UK Gov­ern­ment (the "Gov­ern­ment") is­sued the first wave of its tech­nic­al pa­pers de­signed to provide guid­ance to com­pan­ies to help pre­pare for a "No Deal" Brexit. In this scen­ario, there will be no "trans­ition peri­od" but rather the UK.
    25/01/2018
    European Com­mis­sion as­sesses ad­equacy of Gen­er­al Food Law in food...
    In an eval­u­ation of the EU le­gis­lat­ive frame­work for the 2002 Gen­er­al Food Law Reg­u­la­tion (GFLR), the European Com­mis­sion has found that this frame­work ap­pears to ad­dress most cur­rent trends, such as growth, com­pet­it­ive­ness and in­creased glob­al­isa­tion, but.
    21/06/2017
    The Ver­dict - Round-up of cor­por­ate crime de­vel­op­ments across CMS
    We are pleased to send our new is­sue of The Ver­dict, an at-a-glance round-up of re­cent leg­al de­vel­op­ments in re­la­tion to cor­por­ate crime. In this is­sue, the spot­light is on some sig­ni­fic­ant changes to anti-cor­rup­tion laws in the Czech Re­pub­lic, in­clud­ing.
    06/03/2017
    PIP-case: ECJ cla­ri­fies scope of no­ti­fied body’s re­spons­ib­il­it­ies...
    In the PIP-case, a French man­u­fac­turer sup­plied thou­sands of wo­men with (al­legedly) de­fect­ive breast im­plants. Amongst oth­ers, pa­tients in Ger­many star­ted lit­ig­a­tion against the no­ti­fied body in ques­tion - TÜV Rhein­land (“Tuv”).
    10/02/2017
    In­dia Budget 2017 - 2018
    On 1 Feb­ru­ary, Fin­ance Min­is­ter Ar­un Jait­ley presen­ted In­dia’s an­nu­al Uni­on Budget for 2017-2018 (the “Budget”) for the fisc­al year be­gin­ning 1 April 2017. The cent­ral aim in this year’s Budget ap­pears to fo­cus on the most vul­ner­able with in­creased spend­ing.
    05/12/2016
    ABS Reg­u­la­tion - Draft Bi­otech Sec­tor Stake­hold­er Guid­ance
    Views are be­ing sought from in­ter­ested stake­hold­ers on European guid­ance for the bi­o­tech­no­logy sec­tor con­cern­ing the EU’s ac­cess to ge­net­ic re­sources and shar­ing of be­ne­fits from util­isa­tion le­gis­la­tion – namely the ABS Reg­u­la­tion.
    05/07/2016
    Leg­al de­vel­op­ments in product li­ab­il­ity: With re­strict­ive le­gis­la­tion...
    The med­ic­al in­dustry is un­der in­creas­ing leg­al pres­sure these days ow­ing mainly to a con­sumer-friendly risk en­vir­on­ment. This is evid­ent from re­strict­ive le­gis­la­tion and re­cent land­mark cases, such as the PIP case, con­cern­ing a French com­pany that sup­plied.